The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of five fractions of radiotherapy followed by four cycles of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma: Report of an interim response analysis.
R. J. Myerson
No relevant relationships to disclose
S. R. Hunt
No relevant relationships to disclose
B. R. Tan
No relevant relationships to disclose
P. Parikh
No relevant relationships to disclose
A. C. Lockhart
No relevant relationships to disclose
J. Picus
No relevant relationships to disclose
S. Sorscher
No relevant relationships to disclose
R. Suresh
No relevant relationships to disclose
A. Wang-Gillam
No relevant relationships to disclose
J. W. Fleshman
No relevant relationships to disclose
I. J. Kodner
No relevant relationships to disclose